Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

54.08
+0.39000.73%
Post-market: 54.080.00000.00%19:44 EDT
Volume:1.95M
Turnover:105.64M
Market Cap:13.40B
PE:17.01
High:54.68
Open:53.74
Low:53.70
Close:53.69
52wk High:57.57
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:0.93
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.27
PE(LYR):19.45

Loading ...

Exelixis - No New Safety Signals Identified for Zanzalintinib Plus Atezolizumab in Nlm Subgroup

THOMSON REUTERS
·
Jun 22

How Investors Are Reacting To Exelixis (EXEL) CABOMETYX Neuroendocrine Tumor Phase 3 Win at ASCO

Simply Wall St.
·
Jun 17

How Broad CABOMETYX PFS Benefit At Exelixis (EXEL) Has Changed Its Investment Story

Simply Wall St.
·
Jun 07

Exelixis director Jack L. Wyszomierski sells 3,925 common shares for $198,408.75

Reuters
·
Jun 04

Exelixis director Sue Gail Eckhardt sells 9,812 shares for $491,974.68

Reuters
·
Jun 04

Exelixis announces results from subgroup analysis of Phase 3 Cabinet trial

TIPRANKS
·
May 31

Exelixis - Cabometyx Reduces Risk of Progression or Death by 74% in Non-Functional Net, 60% in Functional Net

THOMSON REUTERS
·
May 30

Exelixis Shareholders Approve Equity Plan and Board Slate

TIPRANKS
·
May 30

Exelixis shareholders approve amended, restated 2017 equity incentive plan at annual meeting

Reuters
·
May 30

Top Exelixis Insider Makes a Major Move With Company Stock

TIPRANKS
·
May 29

Exelixis EVP R&D Aftab Dana disposes of 43,451 common shares for $2.19 million

Reuters
·
May 29

Movement Alert|Exelixis Rises 5.54% in Regular Trading, Trading at $52.88

Market Focus
·
May 29

Exelixis (EXEL) Valuation Check After ASCO 2026 Data Spotlight And New Merck Trial Collaboration

Simply Wall St.
·
May 28

Exelixis to webcast investor conference fireside chats in June

Reuters
·
May 28

Exelixis EVP Commercial Patrick J. Haley sells 32,110 shares for $1.6 million

Reuters
·
May 23

Exelixis to present Cabometyx, zanzalintinib studies at ASCO annual meeting

Reuters
·
May 22

How Investors May Respond To Exelixis (EXEL) Merck MRD+ Colorectal Cancer Trial Collaboration

Simply Wall St.
·
May 21

Top Exelixis Executive Cashes In on Major Stock Sale

TIPRANKS
·
May 20

Exelixis EVP, CFO Christopher Senner disposes 75,793 shares for $3.78 million

Reuters
·
May 20

Exelixis SVP, General Counsel Brenda Hefti disposes 13,036 shares worth $662,202.55

Reuters
·
May 20